Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Breast Neoplasms 117Carcinoma, Non-Small-Cell Lung 66Triple Negative Breast Neoplasms 45Neoplasm Metastasis 45Neoplasms 44Lung Neoplasms 26Ovarian Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Stomach Neoplasms 23Melanoma 16Esophageal Neoplasms 16Adenocarcinoma 15Head and Neck Neoplasms 13Recurrence 12Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Sarcoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Small Cell Lung Carcinoma 10Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 9Urinary Bladder Neoplasms 8Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Inflammatory Breast Neoplasms 7Carcinoma, Pancreatic Ductal 7Breast Neoplasms, Male 7Biliary Tract Neoplasms 7

Interventions

relatlimab 1Ramucirumab 1Nivolumab 1Drug Therapy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastroesophageal Cancer × Albumin-Bound Paclitaxel × Clear all
NCT02317991 2022-07-01

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
65 enrolled 11 charts
Gastrointestinal

Gastroesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡